Cannabis Law Report

SEPTEMBER 2, 2022

The pharmaceutical industry takes a serious economic hit after states legalize marijuana—with an average market loss of nearly $10 billion for drugmakers per each legalization event—according to a first-of-its-kind study. By expanding access and, thus use, legalization could permit cannabis to compete with conventional pharmaceuticals.

Pharmaceutical 52

Pharmaceutical Legalization Marijuana Data 52

Cannabis Law Report

AUGUST 10, 2021

We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

The Cannigma

JUNE 1, 2021

Possessing cannabis is illegal in France, although in 2020, the country changed the law so that the punishment is now a €200 fine. Possessing cannabis is illegal in France, although in 2020, the country changed the law so that the punishment is now a €200 fine. The post Cannabis laws in France appeared first on The Cannigma.

Law 113

Law Epilepsy Programs Patients 113

Cannabis Law Report

SEPTEMBER 29, 2022

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd.

Epilepsy 52

Epilepsy Conditions Media Medicine 52

Cannabis Law Report

DECEMBER 15, 2021

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.

Pharmaceutical 52

Pharmaceutical Cannabinoids Business Extraction 52

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. Eligible patients were granted access to low-THC marijuana oil. Andrew Turnage, the executive director of the Georgia Access to Medical Cannabis Commission, spoke on this fact.

Oil 98

Oil Patients Access THC 98

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

SpeedWeed

APRIL 9, 2021

Although this survey is specifically focused on Texas’ medical marijuana program, it also supports other research showing that cannabis can serve as an effective replacement for pharmaceuticals. This law allows a limited number of patients to use CBD-based medicine with no more than 0.5 percent THC content. View original article.

Pharmaceutical 52

Pharmaceutical Chronic Pain Programs Patients 52

Cannabis Law Report

SEPTEMBER 22, 2021

Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Under the terms of the agreement OCT will use reasonable efforts to develop and commercialise: (i) at least one CBD derivative; (ii) at least one CBG derivative; and (iii) at least one THC derivative, as pharmaceutical drug products.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Unfortunately, this number is expected to increase rapidly with legalized marijuana and access to substances that have five times the THC concentration of regular marijuana,” said Mr. Allen. “We About Anebulo Pharmaceuticals, Inc. and Australia.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

DECEMBER 8, 2021

Global Psychiatry Partnering 2014 to 2021 provides the full collection of Psychiatry disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Access to headline, upfront, milestone and royalty data. Access to hundreds of Psychiatry deal contract documents. Accera Pharmaceuticals.

Access 52

Access Data Pharmaceutical Research and Development 52

Cannabis Law Report

JUNE 1, 2022

This acquisition will accelerate Khiron’s growth in Europe by controlling the complete value chain for its products and gaining direct access to German pharmacies. Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

SpeedWeed

AUGUST 9, 2021

It’s an issue around the world: Governments continue to approve expensive, cannabis-based pharmaceutical products for medicinal use, while cultivation of the plant remains illegal for patients (and their families) to grow at home. Thankfully, Peru recently corrected this problem by passing a law in July that expands cannabis patients’ rights.

Law 52

Law Legalization Hydroponic Medicine 52

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions. Image by Pfüderi from Pixabay.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JULY 5, 2021

Access Control. Since the ERP is equipped with all of the company’s information, the access to data is controlled. and each user can only access part of the information. The QA department usually defines the user access to be controlled and each user will have his. Some users can have unique privileges to.

Pharmaceutical 111

Pharmaceutical Data Access Business 111

Cannabis Law Report

JANUARY 6, 2022

Oregon’s developing psilocybin program is nothing short of revolutionary and provides an opportunity to investigate the potential of psilocybin in treating a myriad of mental health conditions. An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products.

Access 52

Access Patients Research and Development Treatment 52

Cannabis Law Report

SEPTEMBER 8, 2021

Key Transaction Details: The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon’s GMP Manufacturing Facility in Southport , Queensland Australia (the “ Southport Facility ‘).

Access 97

Access Research and Development Medicine THC 97

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

AUGUST 17, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. The live webcast can be accessed here and on the investor page of Marinus’ website. The condition is caused by inherited mutations in either the TSC1 gene or the TSC2 gene. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

LifeCannMD

NOVEMBER 24, 2023

Our patients get a medical marijuana card for various reasons, primarily related to the potential medical benefits of using marijuana for various health conditions. The primary reason our patients choose to get their Medical Marijuana card is to manage symptoms and improve the quality of life for individuals with specific medical conditions.

Marijuana 52

Marijuana Chronic Pain Conditions Strains 52

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

JULY 1, 2021

From their blog… Q&A with Mason Marks on New Psychedelics Law and Regulation Initiative. On June 30th, the Petrie-Flom Center announced the launch of a three-year research initiative , the Project on Psychedelics Law and Regulation (POPLAR) , which is supported by a generous grant from the Saisei Foundation.

Law 105

Law Research and Development Therapy DEA 105

NORML

AUGUST 26, 2019

Virginia has been one of the most reluctant states to consider marijuana law reform, though it recently began allowing some forms of cannabis oil for approved patients. There are currently five “pharmaceutical processor” permit holders in Virginia, and they’re about to open for business.

Marijuana 208

Marijuana Legalization Programs Oil 208

The Cannigma

MARCH 25, 2021

A United Kingdom police chief proposed a novel idea this January: Allow drug-dependent inmates access to free cannabis to help them overcome opioid addiction. This creates a situation where state detention facilities — even where cannabis is legal — do not allow inmates access to medical cannabis because it violates federal law.

Marijuana 145

Marijuana Access Law Pharmaceutical 145

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JUNE 5, 2021

Why does Argentina have the conditions to be an important producer in the cannabis and hemp industry? ” What benefits would the approval of this hemp and cannabis law bring to Argentina? ” What benefits would the approval of this hemp and cannabis law bring to Argentina? ley cáñamo argentina. Read more at [link].

Hemp 105

Hemp Research and Development Pharmaceutical Agriculture 105

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

The Cannigma

JUNE 25, 2022

The country has strict prohibition laws, and violating these can come with fines or hefty jail sentences. Poland established a medical cannabis program in 2017, which allows for a range of cannabis products to be prescribed for a range of medical conditions. These products are typically more accessible in larger cities.

Legalization 108

Legalization Supply Chain Chronic Pain Tincture 108

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

NORML

JANUARY 24, 2019

It seeks to redefine allowed dosage limitations and formulations, and expand patient access and reduce patient cost by adding nurse practitioners and physician assistants to the list of those authorized to issue written certifications to patients.

Policy 157

Policy Patients Education Legislation 157

PrestoDoctor

SEPTEMBER 6, 2023

Traditionally, prescription codeine has been prescribed for a variety of conditions, including post-operative pain, dental procedures, and chronic pain. One of the primary reasons for this shift is the growing acceptance and accessibility of cannabis as an alternative pain management option.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105

MMJ Recs

MARCH 23, 2024

Legalization may offer expanded access to medical cannabis for patients suffering from various conditions, providing alternative treatment options and symptom relief. However, challenges remain in ensuring equitable access to participation in the legal cannabis market and addressing disparities in ownership and representation.

Legalization 52

Legalization Access Programs Education 52

Cannabis Law Report

NOVEMBER 23, 2021

Department of Veterans Affairs (VA) says that while current federal marijuana laws have prevented the department’s physicians from recommending medical cannabis to military veterans, officials are “looking at” the possibility of an internal policy change and have discussed it with the White House. The head of the U.S.

Policy 52

Policy Marijuana Pharmaceutical Treatment 52

Cannabis Law Report

JULY 9, 2021

The state of the law on psychedelic substances is in flux. Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. Some of the most promising substances, and the law applicable to each, are outlined below: Psilocybin.

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

JANUARY 4, 2022

With the conditional approval, ADCL can immediately employ the Linea 2.0 With the conditional approval, ADCL can immediately employ the Linea 2.0 Hayward, president and CEO of Applied DNA, stated, “We are grateful to the NYSDOH for conditional approval of our Linea 2.0 Assay (the “Linea 2.0 The Linea 2.0 Dr. James A.

Conditions 52

Conditions Research and Development Therapy Supply Chain 52